Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05796388 · ClinicalTrials.gov registry record · NA
A Study of Virtual Reality and Linaclotide for IBS-C
A NA study of Irritable Bowel Syndrome With Constipation, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- NA
- Development phase
- 65
- Enrollment target
- 1
- Study location
NCT05796388 is a NA study of Irritable Bowel Syndrome With Constipation that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 65 participants, below the 191-participant average among 3 other Irritable Bowel Syndrome With Constipation trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05796388, a NA study of Irritable Bowel Syndrome With Constipation, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- NA
- Development phase
- 65 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if adult patients with IBS-C will report an overall greater improvement in IBS symptoms and quality of life when treated with a combination of linaclotide (standard of care medication) and immersive virtual reality (VR) therapy compared to those treated with linaclotide and sham (placebo) VR therapy.
Conditions Studied
Interventions
- DEVICE Virtual Reality
Study Locations (1)
Florida
- Mayo Clinic Florida - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2024-05-31 |
| Est. Completion | 2026-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05796388
The ClinicalTrials.gov registry entry for NCT05796388 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 191-participant average among 3 other Irritable Bowel Syndrome With Constipation trials with a reported enrollment target (66% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Irritable Bowel Syndrome With Constipation appearing as the primary indexed condition, and to 1 intervention - of which Virtual Reality is the first listed.
NCT05796388 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT05796388 about?
NCT05796388 is a clinical study titled "A Study of Virtual Reality and Linaclotide for IBS-C". The purpose of this study is to determine if adult patients with IBS-C will report an overall greater improvement in IBS symptoms and quality of life when treated with a combination of linaclotide (standard of care medication) and immersive virtual reality (VR) therapy compared to those treated with...
What is the current status of trial NCT05796388?
This trial is currently recruiting. It is a NA study. The enrollment target is 65 participants. The study started on 2024-05-31. Estimated completion is 2026-06.
What conditions does trial NCT05796388 study?
This clinical trial studies the following conditions: Irritable Bowel Syndrome With Constipation.
What interventions are being tested in trial NCT05796388?
The interventions under investigation include: Virtual Reality (DEVICE).
Who is sponsoring clinical trial NCT05796388?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05796388 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Irritable Bowel Syndrome With Constipation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.